06.04.2021
Scientific Publications
05.13.2021
Design and Demonstration of Potent in vitro and in vivo Activity for CART-ddBCMA, a BCMA-Targeted CAR-T Cell Therapy Incorporating a Non-scFv Binding Domain. 2021 American Society of Gene & Cell Therapy Annual Meeting.
05.13.2021
D Domains: A De Novo Scaffold for the Development of Targeted Therapeutics. 2021 Protein Engineering & Cell Therapy Summit.
04.10.2021
ACLX-001, a novel BCMA-targeted CAR-T cell therapy that can be activated, silenced, and reprogrammed in vivo with soluble protein adapters in a dose dependent manner. Presented at the American Association for Cancer Research 2021 Virtual Annual Meeting, April 10–15, 2021.
12.07.2020
Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain for the treatment of subjects with relapsed and refractory Multiple Myeloma. Data presented at the 62nd American Society of Hematology (ASH) Annual Virtual Meeting, December 5–8, 2020.
06.22.2020
Chimeric antigen receptors incorporating novel binding domains targeting CD123 direct potent antitumor activity of T cells: Correlation between affinity and activity (Abstract 3243). Presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II.
05.29.2020
Selective targeting of HER2-overexpressing solid tumors with a next-generation CAR-T cell therapy (Abstract 3041). Presented at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting.
04.29.2020
Novel CAR-T Cell therapy that can be activated, silenced, and reprogrammed in vivo with soluble protein adapters in a dose dependent manner (Abstract 788). Presented at the American Society of Gene & Cell Therapy (ASGCT) 2020 Annual Meeting.
04.17.2019